Tentamus Group acquires majority stake in Megsan Labs

The acquisition brings complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialization. The expanded service platform will enable Tentamus Pharma to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.

 “We are proud and delighted to welcome the talented team of Megsan Lab and their customers to Tentamus Pharma,” commented Abgar Barseyten, Founder & CEO of Tentamus Group. “Their expertise and capabilities will deepen our current range of services offered to customers. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial and market launch phases of drug development.”

Jayapal Reddy, CEO and Shareholder: “We are proud to have played a crucial role for our customers in many end-markets throughout our history. During the last 5 years, we have made substantial investments into state-of-the-art lab facilities equipped with the best-in-class instrumentation, key scientific talent and industry-leading commercial resources. We share many attributes of Tentamus’s mindset. We are confident that the business is set for a successful and exciting future under the global reach and scientific expertise of Tentamus.” In addition to this, there is no change in key managerial positions, day to day activities will be as usual.

About Megsan Labs

Megsan is a leading US-FDA approved business, which provides analytical testing services to pharmaceutical and related companies. The services comprise elemental impurity studies, E&L studies, method development & validation and microbiological testing. Jayapal Reddy and his wife Jyothirmai Reddy founded the company in 2012. Today Megsan employs more than 140 people.  For further information please visit: www.megsanlabs.com